Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 245 Press Releases

Show

Sort

16 May 2026

Download Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

15 May 2026

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

14 May 2026

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

23 April 2026

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Ipsen Q1 2026 Press Release (251.12 KB)

Ipsen Q1 2026 Highlights (404.22 KB)

Ipsen Q1 2026 Investor presentation (1.05 MB)

22 April 2026

$Download Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration$

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Your dedicated contacts

Sally Bain

Head of Global Media Relations

+1 857 320 0517

sally.bain@ipsen.com

Anne Liontas

France Media Relations

+33 7 67 34 72 96

anne.liontas.ext@ipsen.com

Press Releases

Explore more press releases

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Your dedicated contacts

Sally Bain

Anne Liontas

Stay updated

Press Releases

Explore more press releases

Filter

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

3 related documents/links

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Your dedicated contacts

Sally Bain

Anne Liontas

Stay updated

We value your feedback